logo
  

Ingersoll-Rand Q2 Profit Misses Estimates - Quick Facts

Ingersoll-Rand plc (IR), a world leader in creating comfortable, sustainable and efficient environments, reported second-quarter earnings from continuing operations of $83.0 million, or $0.31 per share compared to $310.6 million or $1.13 per share, last year. Excluding charges, adjusted EPS from continuing operations was $1.20, for the quarter.

On average, 19 analysts polled by Thomson Reuters expected the company to report profit per share of $1.23 for the quarter. Analysts' estimates typically exclude special items.

The company's reported revenues increased 2 percent to $3.60 billion, compared with revenues of $3.54 billion for the 2014 second quarter. Revenues, excluding acquisitions and currency, increased 3 percent compared with last year. Analysts expected revenue of $3.69 billion for the quarter.

Ingersoll-Rand reaffirmed its full-year guidance range for 2015 revenues and for adjusted EPS. Organic revenues, which exclude currency and acquisitions, for the full-year 2015 are expected to increase in the range of 4 to 5 percent. Full-year reported revenues are also expected to increase in the range of 4 to 5 percent compared with 2014. Full-year adjusted EPS from continuing operations are expected to be in the range of $3.66 to $3.81 with full-year reported continuing EPS expected to be $2.59 to $2.74. Analysts expect the company to report earnings per share of $3.79.

Ingersoll-Rand expects third-quarter 2015 organic revenues to increase in the range of 5 to 6 percent compared with 2014 and reported revenues are expected to be up 4 to 5 percent. Adjusted EPS from continuing operations for the third quarter of 2015 are expected to be in the range of $1.15 to $1.19, with reported EPS of $1.13 to $1.17. Analysts expect the company to report earnings per share of $1.20.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT